NASDAQ:SRRK - Scholar Rock Stock Price, Forecast & News

Scholar Rock's stock was trading at $14.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SRRK stock has decreased by 9.7% and is now trading at $13.42. View which stocks have been mosted impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Scholar Rock.

Scholar Rock is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Scholar Rock.

Scholar Rock Holding Corp (NASDAQ:SRRK) released its earnings results on Thursday, March, 12th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.17. The firm earned $7.57 million during the quarter, compared to analyst estimates of $5.45 million. Scholar Rock had a negative return on equity of 44.24% and a negative net margin of 248.88%. View Scholar Rock's earnings history.

3 brokers have issued 1 year target prices for Scholar Rock's shares. Their forecasts range from $27.00 to $35.00. On average, they expect Scholar Rock's share price to reach $31.00 in the next twelve months. This suggests a possible upside of 131.0% from the stock's current price. View analysts' price targets for Scholar Rock.

Press coverage about SRRK stock has trended somewhat negative recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Scholar Rock earned a news impact score of -1.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutScholar Rock.

Scholar Rock saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,901,200 shares, an increase of 6.2% from the February 27th total of 1,790,000 shares. Based on an average daily trading volume, of 80,500 shares, the days-to-cover ratio is currently 23.6 days. Approximately 9.7% of the company's stock are sold short. View Scholar Rock's Current Options Chain.

Some companies that are related to Scholar Rock include Fate Therapeutics (FATE), Bill.com (RVMD), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Regenxbio (RGNX), Editas Medicine (EDIT), Coherus Biosciences (CHRS), I-Mab (BDTX), Twist Bioscience (TWST), NanoString Technologies (NSTG), Beam Therapeutics (BEAM), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), Oyster Point Pharma (OYST) and Krystal Biotech (KRYS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Global Blood Therapeutics (GBT), Coherus Biosciences (CHRS), Exelixis (EXEL), Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Neurocrine Biosciences (NBIX), Nektar Therapeutics (NKTR), Thermo Fisher Scientific (TMO), ACADIA Pharmaceuticals (ACAD) and Atara Biotherapeutics (ATRA).

(SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Scholar Rock's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Norges Bank (1.36%), State Street Corp (1.19%), Victory Capital Management Inc. (0.84%), Victory Capital Management Inc. (0.83%), Geode Capital Management LLC (0.80%) and Jefferies Group LLC (0.42%). Company insiders that own Scholar Rock stock include Amir Nashat and International SCA Artal. View institutional ownership trends for Scholar Rock.

SRRK stock was sold by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Marshall Wace LLP, Nuveen Asset Management LLC, Alberta Investment Management Corp, Panagora Asset Management Inc., and Credit Suisse AG. View insider buying and selling activity for Scholar Rock.

SRRK stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Point72 Asset Management L.P., Victory Capital Management Inc., Victory Capital Management Inc., State Street Corp, Goldman Sachs Group Inc., California Public Employees Retirement System, and Barclays PLC. Company insiders that have bought Scholar Rock stock in the last two years include Amir Nashat, and International SCA Artal. View insider buying and selling activity for Scholar Rock.

Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SRRK stock can currently be purchased for approximately $13.42.

Scholar Rock has a market capitalization of $400.05 million and generates $20.49 million in revenue each year. The company earns $-51,000,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Scholar Rock employs 65 workers across the globe. View additional information about Scholar Rock.

The official website for Scholar Rock is http://www.scholarrock.com/.

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected]